Baseline Clinical and Metabolic Predictors of 52-Week Durability of Secukinumab Response in Moderate-to-Severe Plaque Psoriasis
Clinical, Cosmetic and Investigational Dermatology · 2026-03 · Volume 19 · 1-8
DOI: 10.2147/ccid.s588137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2026-03. Verfasst von Jiayue Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Beijing University of Chinese Medicine, Beijing, People's Republic of China. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing University of Chinese Medicine, Beijing, People's Republic of China.
- Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Institute of Traditional Chinese Medicine, Beijing, People's Republic of China.
ORCID-Profile: Jiayue Wang
Zitieren
APA
Wang, J., & Li, P. (2026). Baseline Clinical and Metabolic Predictors of 52-Week Durability of Secukinumab Response in Moderate-to-Severe Plaque Psoriasis. Clinical, Cosmetic and Investigational Dermatology, Volume 19, 1-8. https://doi.org/10.2147/ccid.s588137
Vancouver
Wang J, Li P. Baseline Clinical and Metabolic Predictors of 52-Week Durability of Secukinumab Response in Moderate-to-Severe Plaque Psoriasis. Clinical, Cosmetic and Investigational Dermatology. 2026;Volume 19:1-8. doi:10.2147/ccid.s588137
BibTeX
@article{Wang2026,
author = {Wang, Jiayue and Li, Ping},
title = {Baseline Clinical and Metabolic Predictors of 52-Week Durability of Secukinumab Response in Moderate-to-Severe Plaque Psoriasis},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2026},
volume = {Volume 19},
pages = {1--8},
doi = {10.2147/ccid.s588137}
}
EUVIMED